Table 2 Comparison of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma or cholangiocarcinoma after propensity score matching
Variable | cHCC-CC (n = 35) | HCC (n = 35) | p value | cHCC-CC (n = 35) | CC (n = 35) | p value |
|---|---|---|---|---|---|---|
Male | 28 (80.0) | 29 (82.9) | 0.759 | 28 (80.0) | 25 (71.4) | 0.339 |
Age (years) | 57 (37–79) | 57 (35–81) | 0.894 | 57 (37–79) | 60 (35–80) | 0.199 |
Smoking | 7 (20.0) | 13 (37.1) | 0.112 | 7 (20.0) | 4 (11.4) | 0.324 |
Alcohol use | 10 (28.6) | 11 (31.4) | 0.794 | 10 (28.6) | 4 (11.4) | 0.209 |
HBV positive | 15 (42.9) | 20 (57.1) | 0.232 | 15 (42.9) | 17 (48.6) | 0.631 |
HCV positive | 8 (22.9) | 5 (14.3) | 0.356 | 8 (22.9) | 13 (37.1) | 0.192 |
Total bilirubin | 0.93 ± 0.32 | 0.85 ± 0.28 | 0.455 | 0.93 ± 0.32 | 0.95 ± 0.45 | 0.861 |
Albumin | 4.1 ± 0.3 | 4.1 ± 0.3 | 0.481 | 4.1 ± 0.3 | 4.2 ± 0.3 | 0.102 |
INR | 1.04 ± 0.04 | 1.06 ± 0.06 | 0.060 | 1.04 ± 0.04 | 1.05 ± 0.11 | 0.446 |
Cirrhosis | 12 (34.3) | 11 (31.4) | 0.799 | 12 (34.3) | 6 (17.1) | 0.107 |
Child–Pugh class A | 35 (100) | 34 (97.1) | 0.801 | 35 (100) | 35 (100) | 1.000 |
Edmondson–Steiner Grades, I–II | 12 (34.2) | 13 (37.5) | 0.313 | 12 (34.2) | 11 (31.4) | 0.861 |
Tumor size | 6.6 ± 3.5 | 7.4 ± 4.3 | 0.055 | 6.6 ± 3.5 | 6.0 ± 2.8 | 0.125 |
Tumor size ≥ 5 cm | 24 (68.6) | 25 (71.4) | 0.794 | 24 (68.6) | 19 (54.3) | 0.220 |
Tumor number (≥ 2) | 3 (8.6) | 6 (17.1) | 0.284 | 3 (8.6) | 1 (2.9) | 0.303 |
AFP (ng/mL) ≥ 200 | 8 (22.9) | 13 (37.1) | 0.192 | 8 (22.9) | 3 (8.6) | 0.101 |
ICG% | 10.7 ± 5.4 | 9.2 ± 5.0 | 0.232 | 10.7 ± 5.4 | 9.3 ± 5.6 | 0.268 |
Operative margin > 1 cm | 12 (34.3) | 11 (31.4) | 0.799 | 12 (34.3) | 18 (51.4) | 0.198 |
Major hepatectomy | 15 (42.8) | 16 (45.7) | 0.783 | 15 (42.8) | 20 (57.1) | 0.328 |
Microvascular invasion | 13 (37.5) | 12 (34.2) | 0.803 | 13 (37.5) | 6 (17.1) | 0.060 |
Macrovascular invasion | 5 (14.3) | 12 (34.2) | 0.056 | 5 (14.3) | 1 (1.9) | 0.088 |
Lympho nodules metastasis | 7 (20.0) | 3 (8.5) | 0.095 | 7 (20.0) | 7 (20.0) | 1.000 |
Distal metastasis | 0 (0) | 0 (0) | 1.000 | 0 (0) | 1 (2.9) | 0.314 |
AJCC stage, I–II | 10 (55.6) | 12 (34.3) | 0.137 | 10 (55.6) | 11 (55.0) | 0.973 |
Antiviral therapy | 15 (42.8) | 16 (45.7) | 0.781 | 15 (42.8) | 20 (57.1) | 0.329 |
Recurrence | 9 (25.7) | 11 (31.4) | 0.597 | 9 (25.7) | 4 (11.4) | 0.124 |
Mortality | 14 (40.0) | 16 (45.7) | 0.629 | 14 (40.0) | 20 (57.1) | 0.151 |
Follow up times (months) | 31 (4–75) | 52 (1–98) | 0.001 | 31 (4–75) | 24 (1–85) | 0.129 |